Korea Stock Market Insights

Tag: Technology Licensing

  • Legochem Bio Enters ADC Collaboration with GO THERAPEUTICS: Investment Analysis



    Legochem Bio Enters ADC Collaboration with GO THERAPEUTICS: Investment Analysis 대표 차트 이미지






    1. What Happened?

    On September 9, 2025, Legochem Bio signed a joint research and antibody technology licensing agreement with GO THERAPEUTICS for the development of new antibody-drug conjugates (ADCs). Through this agreement, Legochem Bio plans to develop new ADCs by incorporating GO THERAPEUTICS’ antibody technology. The agreement is conditional upon regulatory approval and can be terminated if research and development is discontinued or if product approval fails. The financial details of the agreement were not disclosed.

    2. Why Does It Matter?

    This agreement holds significant implications for strengthening and expanding Legochem Bio’s ADC pipeline. The introduction of new antibody technology can complement the existing pipeline and increase the possibility of developing new ADCs. Furthermore, the collaboration with a US biotech company serves as an opportunity to demonstrate Legochem Bio’s technological prowess in the global market and increases the potential for future licensing and commercialization.

    3. So What?

    • Positive Outlook: Successful joint research may lead to the development of new ADC candidates, securing additional milestone and royalty revenue, and strengthening global market competitiveness.
    • Potential Risks: The inherent uncertainties of clinical development, the difficulty in assessing the value due to non-disclosure of the agreement amount, and the volatility of the KRW/USD exchange rate should be considered.

    4. What Should Investors Do?

    This agreement is a positive factor that supports Legochem Bio’s long-term growth potential. However, due to uncertainties such as the progress of clinical development and regulatory approvals, a cautious approach is necessary when making investment decisions. It is crucial to closely monitor future disclosures and market conditions while formulating an investment strategy.



    Frequently Asked Questions (FAQ)

    What is the agreement with GO THERAPEUTICS about?

    It is a joint research agreement for the development of new ADCs and a licensing agreement for Legochem Bio to incorporate GO THERAPEUTICS’ antibody technology.

    Why is this agreement important for Legochem Bio?

    It is expected to contribute to the strengthening and expansion of the ADC pipeline, validation of technological capabilities, and securing future growth engines.

    What are the key points to consider for investment?

    Uncertainties in clinical development, non-disclosure of the agreement amount, and KRW/USD exchange rate fluctuations should be considered.









    Legochem Bio Enters ADC Collaboration with GO THERAPEUTICS: Investment Analysis 관련 이미지




  • Oncocross (382150) H1 2025 Earnings Analysis: AI Drug Discovery Dream vs. Reality

    1. Oncocross H1 2025 Performance: What Happened?

    Oncocross reported revenue of KRW 20 billion (down 14.6% YoY) and an operating loss of KRW 42.55 billion (up 36.6% YoY) in H1 2025. Increased R&D investment (KRW 17.87 billion, +38.6%) and higher SG&A expenses were the primary drivers.

    2. Reasons for Underperformance: Why These Results?

    Oncocross is aggressively investing in enhancing its AI drug discovery platform. While impacting short-term profitability, this investment is crucial for securing long-term growth. Additionally, the inherent nature of drug development means performance can fluctuate significantly depending on clinical trial outcomes and technology licensing agreements.

    3. Oncocross’s Future: What’s Next?

    Leveraging its proprietary AI platforms – RAPTOR AI™, ONCO-RAPTOR AI™, and ONCOfind AI™ – Oncocross is building a diverse drug pipeline. Partnerships with prominent Korean pharmaceutical companies like Hanall Biopharma, Jeil Pharmaceutical, Daewoong Pharmaceutical, Dongwha Pharm, and JW Pharmaceutical validate its technology, and future revenue growth is anticipated through licensing agreements and successful clinical trials. However, the uncertainties of drug development and intensifying competition remain ongoing risks.

    4. Investor Action Plan: What Should Investors Do?

    Investing in Oncocross requires a long-term perspective. The growth potential of AI drug discovery and the company’s technological prowess offer the possibility of high returns, but also entail significant risk. Before investing, carefully monitor the company’s progress, including clinical trial developments, partnerships, and licensing agreements. Thoroughly assess risk factors, including financial stability.

    What are Oncocross’s core technologies?

    Oncocross’s core technologies are its AI-powered drug discovery platforms: RAPTOR AI™, ONCO-RAPTOR AI™, and ONCOfind AI™. These platforms support the entire drug development process, from identifying drug candidates and predicting drug efficacy to designing clinical trials.

    Who are Oncocross’s main partners?

    Oncocross has partnered with leading Korean pharmaceutical companies, including Hanall Biopharma, Jeil Pharmaceutical, Daewoong Pharmaceutical, Dongwha Pharm, and JW Pharmaceutical, for joint research and technology licensing.

    What are the key considerations for investing in Oncocross?

    Investors should consider the high uncertainties of drug development, the potential for clinical trial failures, intensifying competition, and the need for additional funding. Carefully review the company’s financials and business progress before investing.

  • Chong Kun Dang (001630) Q2 2025 Earnings Analysis: Short-Term Setback Amidst Long-Term Growth Potential?

    What Happened?

    Chong Kun Dang reported revenue of KRW 434.8 billion, operating profit of KRW 23.6 billion, and net income of KRW 19.4 billion for Q2 2025. While revenue surpassed market forecasts, operating profit fell short, raising concerns. Notably, sales of key products (Prolia, Atozet, Gliatilin, Januvia, etc.) declined.

    Why These Results?

    The decline in sales of key products led to an overall deterioration in profitability. However, R&D investment for future growth drivers continued at the previous year’s level. The global licensing of CKD-510 is considered a positive achievement. However, operating cash flow turned negative due to declining sales and increased R&D investment.

    What’s Next?

    In the short term, sluggish sales of major products and lower-than-expected operating profit could negatively impact stock prices. However, continued R&D investment and successful technology licensing suggest long-term growth potential. The performance of new pipelines and strategic execution capabilities will determine Chong Kun Dang’s future growth trajectory. Currently, the debt-to-equity ratio remains stable at 64.00%, but fluctuations in exchange rates and oil prices could pose potential burdens on profitability.

    What Should Investors Do?

    Rather than reacting to short-term stock price fluctuations, investors should focus on Chong Kun Dang’s R&D capabilities and new drug development pipeline. The success of innovative drug development will determine the long-term investment value. It’s crucial to continuously monitor the progress of the new pipeline and management’s strategic announcements.

    Q: What are the key takeaways from Chong Kun Dang’s Q2 earnings?

    A: Revenue exceeded expectations, but operating profit fell short due to declining sales of key products. However, R&D investment remains strong, and there’s been success in technology licensing.

    Q: What is the outlook for Chong Kun Dang’s future growth?

    A: Continued R&D investment and successful tech licensing point to long-term growth potential, but the performance of new pipelines is a crucial factor.

    Q: What should investors pay attention to?

    A: Focus on R&D capabilities and the drug development pipeline rather than short-term stock price movements. Monitoring the new pipeline’s progress and management’s strategic announcements is key.